Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32369| Title: | Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography. | Austin Authors: | Dickmann, Catherine G Fitzgerald;McDonald, Alexander F;Huynh, Nhi;Rigopoulos, Angela;Liu, Zhanqi;Guo, Nancy;Osellame, Laura D;Gorman, Michael A;Parker, Michael W;Gan, Hui K ;Scott, Andrew M ;Ackermann, Uwe ;Burvenich, Ingrid J G;White, Jonathan M | Affiliation: | Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia. Olivia Newton-John Cancer Research Institute Molecular Imaging and Therapy School of Cancer Medicine, La Trobe University, Australia. |
Issue Date: | 9-Mar-2023 | Date: | 2023 | Publication information: | Chemical communications (Cambridge, England) 2023; 59(21): 3126-3129 | Abstract: | Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been targeted for molecular imaging of cancer. Here, we report the development of a novel molecule radiolabelled with positron emitting fluorine-18, [18F]BiPET-2, and its in vitro and preclinical evaluation in glioblastoma models. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32369 | DOI: | 10.1039/d2cc04813b | ORCID: | 0000-0002-8829-5354 0000-0001-5261-8118 0000-0001-6174-3797 0000-0003-3438-8245 0000-0002-3101-1138 0000-0001-7319-8546 0000-0002-6656-295X 0000-0001-9259-2258 0000-0001-8384-2403 0000-0002-0707-6257 |
Journal: | Chemical communications (Cambridge, England) | Start page: | 3126 | End page: | 3129 | PubMed URL: | 36809538 | ISSN: | 1364-548X | Type: | Journal Article | Subjects: | Positron-Emission Tomography/methods Glioblastoma/diagnostic imaging |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.